title: Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
abstract: OBJECTIVE
  Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-α (TNFα), was evaluated as maintenance therapy in TNFα antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy.
  
  
  METHODS
  We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment, eg, PURSUIT). Patients who responded to induction therapy with golimumab (n = 464) were assigned randomly to groups given placebo or injections of 50 or 100 mg golimumab every 4 weeks through week 52. Patients who responded to placebo in the induction study continued to receive placebo. Nonresponders in the induction study received 100 mg golimumab. The primary end point was clinical response maintained through week 54; secondary end points included clinical remission and mucosal healing at both weeks 30 and 54.
  
  
  RESULTS
  Clinical response was maintained through week 54 in 47.0% of patients receiving 50 mg golimumab, 49.7% of patients receiving 100 mg golimumab, and 31.2% of patients receiving placebo (P = .010 and P < .001, respectively). At weeks 30 and 54, a higher percentage of patients who received 100 mg golimumab were in clinical remission and had mucosal healing (27.8% and 42.4%) than patients given placebo (15.6% and 26.6%; P = .004 and P = .002, respectively) or 50 mg golimumab (23.2% and 41.7%, respectively). Percentages of serious adverse events were 7.7%, 8.4%, and 14.3% among patients given placebo, 50 mg, or 100 mg golimumab, respectively; percentages of serious infections were 1.9%, 3.2%, and 3.2%, respectively. Among all patients given golimumab in the study, 3 died (from sepsis, tuberculosis, and cardiac failure, all in patients who received 100 mg golimumab) and 4 developed active tuberculosis.
  
  
  CONCLUSIONS
  Golimumab (50 mg or 100 mg) maintained clinical response through week 54 in patients who responded to induction therapy with golimumab and had moderate-to-severe active ulcerative colitis; patients who received 100 mg golimumab had clinical remission and mucosal healing at weeks 30 and 54. Safety was consistent with that reported for other TNFα antagonists and golimumab in other approved indications. ClinicalTrials.gov number: NCT00488631.
authors.affiliation: Division of Gastroenterology, University of California San Diego, La Jolla, California. Electronic address: wsandborn@ucsd.edu.
authors.forename: William J
authors.initials: WJ
authors.lastname: Sandborn
authors.affiliation: Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
authors.forename: Brian G
authors.initials: BG
authors.lastname: Feagan
authors.affiliation: Janssen Research and Development, LLC, Spring House, Pennsylvania.
authors.forename: Colleen
authors.initials: C
authors.lastname: Marano
authors.affiliation: Janssen Research and Development, LLC, Spring House, Pennsylvania.
authors.forename: Hongyan
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Janssen Research and Development, LLC, Spring House, Pennsylvania.
authors.forename: Richard
authors.initials: R
authors.lastname: Strauss
authors.affiliation: Janssen Research and Development, LLC, Spring House, Pennsylvania.
authors.forename: Jewel
authors.initials: J
authors.lastname: Johanns
authors.affiliation: Janssen Research and Development, LLC, Spring House, Pennsylvania.
authors.forename: Omoniyi J
authors.initials: OJ
authors.lastname: Adedokun
authors.affiliation: Janssen Services, LLC, Horsham, Pennsylvania.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Guzzo
authors.affiliation: Department of Hepatogastroenterology and Centre d'Investigation Clinique Centre Hospitalier Universitaire de Lille, Université Lille Nord de France, Lille, France; Icahn School of Medicine at Mount Sinai, New York, New York.
authors.forename: Jean-Frederic
authors.initials: JF
authors.lastname: Colombel
authors.affiliation: Department of Gastroenterology and Hepatology, Universitätsklinik für Innere Medizin III, Vienna, Austria.
authors.forename: Walter
authors.initials: W
authors.lastname: Reinisch
authors.affiliation: Department of Gastroenterology, Monash University, Alfred Hospital, Melbourne, Victoria, Australia.
authors.forename: Peter R
authors.initials: PR
authors.lastname: Gibson
authors.affiliation: Division of Gastroenterology, Department of Medicine, Oregon Health Sciences University, Portland, Oregon.
authors.forename: Judith
authors.initials: J
authors.lastname: Collins
authors.affiliation: Division of Gastroenterology, Department of Medicine, Örebro University Hospital, Örebro, Sweden.
authors.forename: Gunnar
authors.initials: G
authors.lastname: Järnerot
authors.affiliation: Department of Gastroenterology, University Hospital, Gasthuisberg, Leuven, Belgium.
authors.forename: Paul
authors.initials: P
authors.lastname: Rutgeerts
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D060046:Maintenance Chemotherapy / Q000379:methods; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000305:Adrenal Cortex Hormones; D000636:Aminosalicylic Acids; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab; D015122:Mercaptopurine; D008727:Methotrexate
keywords: Fully Human Monoclonal Antibody; IV; Inflammatory Bowel Disease; NNT; PURSUIT; PURSUIT-M; Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment; Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment Maintenance; Randomized Withdrawal Trial; SC; TNFα; UC; intravenous; number needed to treat; subcutaneous; tumor necrosis factor-α; ulcerative colitis